IDEAYA Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, IDEAYA Biosciences sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 8 currently recruiting early-phase tilt top decile by trial count

IDEAYA Biosciences: 10 sponsored US clinical trials, 8 recruiting.

IDEAYA Biosciences sponsors 10 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Uveal Melanoma, with 2 trials.

Top-decile sponsor footprint

IDEAYA Biosciences ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

NCT07540572
RECRUITING Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413
RECRUITING Phase 1

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

NCT07503808
RECRUITING Phase 3

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
RECRUITING Phase 1

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

NCT07174583
RECRUITING Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587
RECRUITING Phase 1

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

NCT04794699
RECRUITING Phase 1

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385
ACTIVE NOT RECRUITING Phase 2

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332
ACTIVE NOT RECRUITING Phase 2

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT05907954

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 2
Phase 3 1

Therapeutic Areas

Metastatic Uveal Melanoma 2
Uveal Melanoma 2
Colorectal Cancer 2
Squamous Cell Car. - Esophagus 1
Adenocarcinoma of Esophagus 1
Gastroesophageal Cancer (GC) 1
Urothelial Carcinoma (UC) 1
NSCLC Adenocarcinoma 1
Pleural Mesothelioma 1
Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1

What is open in the IDEAYA Biosciences pipeline

8 recruiting of 10 indexed (80% open).

Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Metastatic Uveal Melanoma (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

IDEAYA Biosciences: open-pipeline peers nationwide

Peers matched on 10 registered trials and 80% open enrollment, not the therapeutic-area sidebar.

IDEAYA Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%20%40%60%80%100% Total trials Recruiting share IDEAYA BiosciencesAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAlpha Tau MedicalBuck Institute for Research on AgingMapLight TherapeuticsMirador Therapeutics
IDEAYA Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

IDEAYA Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 80% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this IDEAYA Biosciences page

10 registered trials is a research-attention snapshot, not an endorsement of IDEAYA Biosciences or any single study.

  • 8 of IDEAYA Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Metastatic Uveal Melanoma is the condition IDEAYA Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Uveal Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

IDEAYA Biosciences pipeline card: 10 registered trials from official public datasets.Report a data error.